Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of HS-20090-2 vs Prolia in Healthy Adults
NCT04940845Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of HS-20090 in postmenopausal osteoporosis (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Area under the plasma concentration-infinity curve at 155 days and Maximum Plasma Concentration at 155 days. Status: unknown.
02
Drugs
HS-20090
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04940845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940845.